Timing of SGLT2i initiation after acute myocardial infarction

Article Pharmacology & Pharmacy

Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry

Pasquale Paolisso et al.

Summary: In T2DM patients presenting with AMI, the use of SGLT2-I was associated with better in-hospital and long-term prognosis compared to non-SGLT2-I users.

PHARMACOLOGICAL RESEARCH (2023)

Add to Collection

Article Medicine, General & Internal

SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes

Raffaele Marfella et al.

Summary: This study evaluated the incidence of intra-stent restenosis (ISR)-related events in patients with type 2 diabetes (T2DM) and acute myocardial infarction (AMI) treated or not with sodium/glucose cotransporter 2 inhibitors (SGLT2i). The results showed that the use of SGLT2 inhibitors in patients with T2DM is associated with a reduced incidence of ISR-related events, independent of glycemic control.

BMC MEDICINE (2023)

Add to Collection

Review Cardiac & Cardiovascular Systems

Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms

Keming Huang et al.

Summary: Among the complications of diabetes, cardiovascular events and cardiac insufficiency are important causes of death. SGLT2i treatment has been shown to improve cardiac dysfunction and benefit various factors related to diabetic cardiomyopathy, such as metabolism, microcirculation, mitochondrial function, fibrosis, oxidative stress, endoplasmic reticulum stress, programmed cell death, autophagy, and intestinal flora.

CARDIOVASCULAR DIABETOLOGY (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis

Celestino Sardu et al.

Summary: This study assessed the effects of SGLT2-I therapy on Mv-NOCS patients and found that it significantly reduces the risk of major adverse cardiovascular events by improving glucose homeostasis, reducing systemic inflammation, and affecting the inflammation, lipid accumulation, and fibrous cap thickness of atherosclerotic plaques.

CARDIOVASCULAR DIABETOLOGY (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction - a post-hoc analysis of the EMMY trial

Martin Benedikt et al.

Summary: The EMMY trial investigated the impact of Empagliflozin on inflammatory biomarkers in post-AMI patients, and found that there was no significant difference in the reduction of these biomarkers compared to placebo.

CARDIOVASCULAR DIABETOLOGY (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial

Faisal J. Aziz et al.

Summary: This study explored the relationship between SGLT2 inhibitors and TMAO after acute myocardial infarction (AMI) and found that SGLT2i treatment significantly increased TMAO levels compared to standard post-MI treatment. Age was positively associated with TMAO, while eGFR and LVEF were negatively associated with TMAO. Further research is needed to investigate the impact of SGLT2i therapy on acute and long-term changes in TMAO in cardiovascular cohorts.

CARDIOVASCULAR DIABETOLOGY (2023)

Add to Collection

Article Critical Care Medicine

Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study

Johan Martensson et al.

Summary: This pilot study assessed the safety of empagliflozin therapy in ICU patients with type 2 diabetes. The results showed that although empagliflozin therapy was associated with increased sodium and chloride levels, it was not significantly associated with acid-base changes, hypoglycemia, ketoacidosis, worsening kidney function, bacteriuria, or mortality.

CRITICAL CARE (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial

Josephine Harrington et al.

Summary: The EMPACT-MI trial aims to evaluate the efficacy and safety of empagliflozin in high-risk patients after an acute myocardial infarction. The results of this trial will have important implications for clinical practice.

AMERICAN HEART JOURNAL (2022)

Add to Collection

Article Biochemistry & Molecular Biology

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Adriaan A. Voors et al.

Summary: The sodium-glucose cotransporter 2 inhibitor empagliflozin improves clinical outcomes in patients hospitalized for acute heart failure, regardless of ejection fraction or the presence of diabetes.

NATURE MEDICINE (2022)

Add to Collection

Review Endocrinology & Metabolism

Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence

Kamlesh Khunti et al.

Summary: SGLT2 inhibitors are an important part of type 2 diabetes therapy, with benefits for cardiovascular and kidney outcomes. The risk of DKA is low in those using SGLT2 inhibitors, but higher compared to placebo. In COVID-19 cases, SGLT2 inhibitors may have potential benefits with low rates of DKA.

DIABETES OBESITY & METABOLISM (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Empagliflozin in acute myocardial infarction: the EMMY trial

Dirk von Lewinski et al.

Summary: This study investigated the effects of empagliflozin on patients following acute myocardial infarction, showing significant reductions in NT-proBNP and improvements in echocardiographic parameters.

EUROPEAN HEART JOURNAL (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis

Bo Xiong et al.

Summary: This meta-analysis suggests that early administration of sacubitril-valsartan may be superior to conventional ACEI/ARB to decrease the risk of hospitalization for HF, improve the cardiac function, and reverse the LV remodelling in patients following AMI.

ESC HEART FAILURE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Jean-Philippe Collet et al.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Article Endocrinology & Metabolism

15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2021

Summary: The ADA Standards of Medical Care in Diabetes provides recommendations for diabetes care and is updated annually by the Professional Practice Committee. Readers can provide feedback on the Standards on the professional website.

DIABETES CARE (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis

Bo Xiong et al.

Summary: Sacubitril-valsartan may be superior to conventional ACEI/ARB in reducing the risk of hospitalization for HF, improving cardiac function, and reversing LV remodelling in patients following AMI, without increasing the risk of adverse events such as hypotension, hyperkalaemia, angioedema, and cough.

ESC HEART FAILURE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems